Sage Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – SAGE
NEW YORK, NY / ACCESSWIRE / May 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws.
Before the market opened on April 17, 2024, Sage issued a press release "announc[ing] . . . topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral medicine dalzanemdor (SAGE-718) in people with mild cognitive impairment (MCI) in Parkinson 's Disease (PD)." Sage stated that "[t]he PRECEDENT Study did not meet its primary endpoint of demonstrating statistically significant difference from baseline in participants treated with once-daily dalzanemdor versus placebo".
On this news, Sage 's stock price fell $3.06 per share, or 19.58%, to close at $12.57 per share on April 17, 2024. To obtain additional information, go to:
https://zlk.com/pslra-1/sage-therapeutics-lawsuit-submission-form?prid=78395&wire=1
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.
WHY LEVI & KORSINSKY:Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services ' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE:Levi & Korsinsky, LLP
View the original press release on accesswire.com
© 2024 Accesswire. All Rights Reserved.